ALBUTEROL SULFATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Albuterol Sulfate, and when can generic versions of Albuterol Sulfate launch?
Albuterol Sulfate is a drug marketed by Cipla, Lupin, Padagis Us, Sandoz Inc, Actavis Mid Atlantic, Akorn, Apotex Inc, Bausch And Lomb, Copley Pharm, Landela Pharm, Luoxin Aurovitas, Mylan Speclt, Nephron, Ritedose Corp, Roxane, Sun Pharm, Teva Pharms, Watson Labs, Watson Labs Inc, Wockhardt Eu Operatn, Amneal Pharms, Chartwell Rx, Cosette, Lannett Co Inc, Mova, Quagen, Teva, Rising, Am Therap, Amneal Pharms Co, Appco, Aurobindo Pharma Ltd, Eywa, Mylan, Pliva, Strides Pharma, Sun Pharm Industries, Ucb Inc, Virtus Pharm, Warner Chilcott, Zydus Pharms, Fosun Pharma, and Watson Labs Teva. and is included in eighty NDAs.
The generic ingredient in ALBUTEROL SULFATE is albuterol sulfate; ipratropium bromide. There are thirty-eight drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Albuterol Sulfate
A generic version of ALBUTEROL SULFATE was approved as albuterol sulfate; ipratropium bromide by CIPLA on December 31st, 2007.
Summary for ALBUTEROL SULFATE
US Patents: | 0 |
Applicants: | 43 |
NDAs: | 80 |
Finished Product Suppliers / Packagers: | 31 |
Raw Ingredient (Bulk) Api Vendors: | 74 |
Clinical Trials: | 43 |
Patent Applications: | 5,851 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ALBUTEROL SULFATE |
Drug Sales Revenues: | Drug sales revenues for ALBUTEROL SULFATE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ALBUTEROL SULFATE |
What excipients (inactive ingredients) are in ALBUTEROL SULFATE? | ALBUTEROL SULFATE excipients list |
DailyMed Link: | ALBUTEROL SULFATE at DailyMed |


See drug prices for ALBUTEROL SULFATE

Recent Clinical Trials for ALBUTEROL SULFATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Aurobindo Pharma Ltd | Phase 3 |
Teva Branded Pharmaceutical Products R&D, Inc. | Early Phase 1 |
University of North Carolina, Chapel Hill | Early Phase 1 |
Pharmacology for ALBUTEROL SULFATE
Drug Class | beta2-Adrenergic Agonist |
Mechanism of Action | Adrenergic beta2-Agonists |
Paragraph IV (Patent) Challenges for ALBUTEROL SULFATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
PROVENTIL-HFA | Inhalation Aerosol | albuterol sulfate | 0.09 mg base per actuation | 020503 | 1 | 2015-05-20 |
PROAIR HFA | Inhalation Aerosol | albuterol sulfate | 0.09 mg base per actuation | 021457 | 1 | 2012-05-18 |
ACCUNEB | Inhalation Solution | albuterol sulfate | 0.021% | 020949 | 1 | 2005-10-19 |
ACCUNEB | Inhalation Solution | albuterol sulfate | 0.042% | 020949 | 1 | 2004-04-06 |